Cure Today

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
CURE

Learning I Had a BRCA1 Mutation Changed My Breast Cancer Risk

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.
Seeking Alpha

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...
News-Medical.Net on MSN

How somatic mutations shape disease and reveal new drug targets

By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...
Business Insider

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response ...
ascopubs.org

Ten Years After Mutation Testing for Lynch Syndrome: Cancer Incidence and Outcome in Mutation-Positive and Mutation-Negative Family Members

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer Cancer incidence and survival were ...
Medscape

Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...
Business Wire

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Monthly Prescribing Reference

Tagrisso Approved for First-Line Tx of EGFR Mutation Positive Advanced NSCLC

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
AOL

Mom writes another children's book after testing positive for BRCA2 mutation

Ashley Dedmon’s parents always told her knowledge is power. Discussions about health, she says, were the norm growing up. “They were educators,” Dedmon says of her parents. “They were always wanting ...
Nasdaq

FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...